Vancomycin intermediate resistant *Staphylococcus aureus* in the nasal cavity of asymptomatic individuals: a potential public health challenge

Morenike Adeoye-Isijola¹, Olufunmiso Olajuyigbe¹³, Kehinde Adebola², Roger Coopoosamy³, Anthony Afolayan⁴

1. Department of Microbiology, School of Science & Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.
2. Department of Public Health, Babcock University, Ilisan Remo, Ogun State, Nigeria.
3. Department of Nature Conservation, Faculty of Natural Sciences, Mangosuthu University of Technology, P.O. Box 12363, Jacobs, 4026, Durban, Kwa-Zulu Natal, South Africa
4. Medicinal Plants and Economic Development (MPED) Research Centre, Botany Department, University of Fort Hare, Alice Campus, South Africa

Abstract

**Background:** The potential of transmitting multidrug resistant *Staphylococcus aureus* from asymptomatic individuals to healthy individuals could constitute a great challenge to antimicrobial therapy.

**Methods:** The antibiograms of the *S. aureus* from asymptomatic individuals were determined by disk diffusion and agar dilution assay techniques with different antibiotics and vancomycin.

**Results:** Of the 152 *S. aureus* isolated, (59)38.8% isolates were multi-drug resistant strains. Streptomycin was the most effective and inhibited (135)88.82% of the isolates while ceftazidime inhibited (24)15.8% of the isolates. While (82)54.0% of the isolates inhibited by cefuroxime had resistant colonies within their inhibition zones (Rc) and ofloxacin inhibited (100)65.8% of the isolates without having resistant colonies within the inhibition zones. Subjecting the isolates to vancomycin showed that (27)17.8% were resistant to 2 µg/ml, (43)28.3% were resistant to 4 µg/ml and (27)17.8% of the isolates were simultaneously resistant to both concentrations of vancomycin. Although (100)65.8% of the isolates had MAR\textsuperscript{index} ≥0.2, (52)34.2% of the isolates had MAR\textsuperscript{index} ≤ 0.2 and (65)42.8% of the isolates were considered multidrug resistant strains.

**Conclusion:** The isolation of multi-drug and vancomycin intermediate resistant strains of *S. aureus* in high percentage, in this study, presents a great threat to clinicians and general populace. The vancomycin intermediate resistant *S. aureus* (VISA) in asymptomatic individuals could be a critical concern to the therapeutic dilemma to be added to the presence of multi-drug resistance. A more sustainable therapy must be in place to prevent its dissemination or the outbreak of its infection.

**Keywords:** Antibacterial activity, multidrug resistance, VRSA, VISA, vancomycin

**DOI:** [https://doi.org/10.4314/ahs.v20i3.12](https://doi.org/10.4314/ahs.v20i3.12)

**Cite as:** Adeoye-Isijola M, Olajuyigbe O, Adebola K, Coopoosamy R, Afolayan A. Vancomycin intermediate resistant *Staphylococcus aureus* in the nasal cavity of asymptomatic individuals: a potential public health challenge. Afr Health Sci. 2020;20(3): 1109-1117. [https://dx.doi.org/10.4314/ahs.v20i3.12](https://dx.doi.org/10.4314/ahs.v20i3.12)

**Introduction**

*Staphylococcus aureus*, being the most important *Staphylococcaceae* species, can be found in both healthy and immunocompromised individuals.¹ Its ecological niches are the anterior nares and most of invasive *S. aureus* infections are assumed to arise from nasal carriages.² Both methicillin-resistant and methicillin-sensitive strains can be found as normal commensals on the skin, the nasopharynx and anterior nares of many asymptomatic individuals who can, possibly, transmit methcillin-resistant *S. aureus* (MRSA) to healthy and immunocompromised persons in hospitals¹³ by direct contact.

The emergence of high levels of penicillin resistance has made the therapy of staphylococcal disease a global challenge. Methicillin-resistant *Staphylococcus aureus* (MRSA), so far restricted to hospitals,³ was first reported in 1961 soon after methicillin was introduced in 1951 to treat penicillin-resistant *staphylococci*.² In the 1980s, due to widespread methicillin use, MRSA became a major problem globally⁴ and glycopeptides became antibiotics of choice for the empiric treatment of infections caused by MRSA in many health-care institutions.

**Corresponding author:**
Olufunmiso Olajuyigbe,
Department of Microbiology;
School of Science & Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.
Email: funmijuyigbe12@yahoo.com
Despite the fact that vancomycin resistant strains of coagulase-negative *Staphylococcus* have been a cause of concern, there was a temporary relief to the medical community when vancomycin, a glycoprotein able to inhibit the growth of all strains of MRSA, was discovered and used in many countries. However, the first strain of *S. aureus* with reduced susceptibility to vancomycin and teicoplanin was soon reported in Japan while vancomycin-resistant *S. aureus* (VRSA) was later reported in Belgium, Germany, United States, Brazil and Jordan. The early 1990s saw a discernible increase in vancomycin use, and established selective pressure that resulted in the emergence of resistant strains of *S. aureus* and other species of *Staphylococcus* with decreased susceptibility to vancomycin. Resistance of VRSA to many antimicrobial agents also posed a great danger to the patients because of the virulence of the organism.

Vancomycin, a tricyclic glycopeptide antibiotic, has been the cornerstone for treating MRSA infections. Over recent years, however, there has been a gradual decrease in the susceptibility of MRSA for a number of reasons. These include relatively poor tissue penetration, slow bacterial killing and the potential for its toxicity all of which have limited the use of vancomycin in the management of MRSA infections. Its efficacy against MRSA was reported to be inferior to that of beta-lactams used against methicillin susceptible *S. aureus* (MSSA) due to its slower in vitro bacterial activity with a lower clinical response. Thus, vancomycin treatment failures have been reported in patients infected with susceptible isolates with MIC values of 1.5 to 2.0 µg/ml in addition to the presence of vancomycin-intermediate *S. aureus* (VISA) and heteroresistance VISA being associated with horrific clinical outcomes. Considering the clinical relevance of multi-drug resistance amongst bacteria and the possible complications that may be caused by the development of VISA and VRSA, there is a need to determine the presence or absence of multi-drug, VISA and VRSA in these individuals that might constitute a reservoir for the dissemination of this pathogen. This is to forestall their treatment failures and transmission from asymptomatic to symptomatic individuals. This study, therefore, investigated multi-drug resistance pattern of *S. aureus* from the nares of asymptomatic individuals and determined their degree of susceptibility to vancomycin.

**Materials and methods**

**Sample collection**

After signing the informed consent previously approved by the Babcock University Research and Ethics Committee (BUREC), samples were collected from 250 asymptomatic individuals in Babcock University, Ogun State, Nigeria between September 2016 and May 2017. Individuals who have been treated with any antibiotic in the last 4 weeks were excluded. The samples were carefully collected by rolling swab saturated with sterile peptone water in the nostrils of 250 undergraduate healthy individuals after seeking and obtaining their individual verbal and signed written consent. The swabs were tightly sealed and immediately transported to the laboratory. The collected nasal swab sticks were streaked on mannitol salt agar (Oxford CM0085 – Oxoid Ltd. Wade Road, Basingstoke, Hants, RG24 8PW, UK (MSA)) and nutrient agar (LAB M -620 Lesher Place, Lansing, MI 48912 USA) which were incubated overnight at 37°C for 24 – 48 h. The bacterial colonies were subjected to Gram staining, microscopic appearance, colony morphology and biochemical tests such as tube coagulase test, catalase test and DNase test according to standard protocols.

**Antibiogram study of the isolates from the nasal swabs using multi-disc antibiotics**

The standard disc diffusion test was performed according to the recommendations of the Clinical Laboratory Standards Institute. Four separated colonies of each of the isolates from nutrient agar were homogenized with inoculating loop in 2 mL sterile normal saline and vortexed to obtain uniform bacterial suspensions. Each strain's suspension was adjusted to 0.5 McFarland Standards by adding more organisms if the suspensions were too light or by diluting further with sterile saline if the suspensions were too heavy to give a resultant concentration of 1.5 × 10^6 cfu/ml. The antibacterial activity was determined according to the modified Kirby–Bauer disk diffusion technique. The Mueller–Hinton agar (MHA) (Oxford CM0085 – Oxoid Ltd. Wade Road, Basingstoke, Hants, RG24 8PW, UK) plates were swabbed with the resultant adjusted culture of each of the test isolates. With sterile forceps, commercial antibiotics (Abtek) containing different antibiotics including ceftazidime (Cef) (30 µg), cefuroxime (Cfx) (30 µg), gentamicin (Gen) (10 µg), ceftriaxone (Cft) (30 µg), erythromycin (Ery) (5 µg), cloxacillin (Clx) (5 µg), ofloxacin (Ofl) (5 µg), augmentin (Aug) (30 µg), cotrimoxazole (Cot) (25 µg), streptomycin (Str) (10 µg), tetracycline (Tet) (10 µg) and chloramphenicol (Chl) (10 µg) were aseptically placed on the inoculated agar and incubated at 37°C for 24 h. After 24 h of incubation, the plates were examined for inhibition zones. The diameter of
the inhibition zones produced by each antibiotic disk were measured to the nearest millimeter, recorded and interpreted using the Clinical and Laboratory Standards Institute Zone Diameter Interpretative Standards. Resistant colonies (Rc) isolated from within inhibition zones were further identified to be coagulate positive S. aureus. Each bacterial isolate was classified as susceptible (S), intermediate (I) and resistant (R) to antibiotics according to the zone diameter interpretation standard recommended by the Clinical Laboratory Standards Institute.

Multiple antibiotic resistance index (MAR index) of S. aureus from nasal cavity
The Multiple Antibiotic Resistance (MAR Index) of each isolate was calculated as the number of antibiotics to which the isolate is resistant divided by the total number of antibiotics to which it is exposed as indicated by Krumpelman. According to Adeleke and Omafuvbe, isolates with MAR index ≤0.2 might have come from individuals using antibiotics infrequently while one with MAR index >0.2 may have come from individuals using antibiotics more frequently.

Susceptibility test of samples to vancomycin
The susceptibility of coagulate positive isolates was further determined by agar dilution method according to the guidelines of CLSI. The isolates were subjected to susceptibility testing with 2 µg/ml and 4 µg/ml concentrations of vancomycin prepared by dissolving 0.4 mg of vancomycin into 200 ml of sterilized Mueller Hinton agar maintained at a temperature of 50°C. The overnight broth culture of each isolate was then adjusted to match up with 0.5 McFarland standards to give a resultant concentration of 1.5 × 10^6 cfu/ml before being inoculated and incubated at 37°C for 24 h by streaking the vancomycin-containing agar surfaces.

Results
In this study, 152 coagulate positive isolates were identified as Staphylococcus aureus. Being resistant to three classes of antibiotics (59)38.8% of these isolates were multi-drug resistant strains. The susceptibility of the isolates to the different antibiotics showed that streptomycin was the most effective. It inhibited (135)88.8% of the isolates. This was followed in a descending order by chloramphenicol (133)87.5% > ofloxacin (124)81.6% > erythromycin (112)73.7% > gentamicin (108)71.1% > cotrimoxazole (81)53.3% > cefuroxime (78)51.3% > tetracycline (76)50% > ceftriaxone (75)49.3% > augmentin (52)34.2% > cloxacillin (51)33.6% > ceftazidime (24)15.8%. Although these antibodies inhibited the isolates with some of the isolates having resistant colonies (Rc) within their inhibition zones, ofloxacin inhibited the highest percentage (100)65.8% of the isolates without having resistant colonies within the inhibition zones. The ofloxacin was followed in a descending order by streptomycin (98)64.5% > chloramphenicol (93)61.2% > gentamicin (76)50% > erythromycin (59)38.8% > ceftriaxone (38)25.0% > cotrimoxazole (28)18.4% > cefuroxime (22)14.5% > ceftazidime (7)4.4%) which inhibited the least number of isolates without resistant colonies within the inhibition zones. Comparatively, highest number (109)71.7% of strains were resistant to ceftazidime. This is followed by (92)60.5% for cloxacillin > (74)48.7% for augmentin > (66)43.4% for tetracycline > (63)41.5% for cefuroxime > (60)39.5% for cotrimoxazole > (56)36.8% for augmentin (54)29.6% for chloramphenicol (43)20.8% > cloxacillin (38)25% > ofloxacin (37)24.3% > ceftazidime (33)21.7% > streptomycin (22)14.5% as shown in Figure 1.
The antibiotics, number of classes of antibiotics and multidrug resistance index (MAR\textsubscript{index}) of the \textit{S. aureus} from asymptomatic nasal cavity are presented in Table 1. In this table, (54)35.5\% of the isolates had MAR\textsubscript{index} \leq 0.2 while (98)64.5\% of the isolates had MAR \geq 0.2. Of the (54)35.5\% with MAR \leq 0.2, (28)53.9\% had their MAR\textsubscript{index} equal to 0 implying that these isolates were not resistant to any of the antibiotics. While the MAR\textsubscript{index} of 0.125 showed that (26)17.1\% of the isolates was resistant to at least two antibiotics and MAR\textsubscript{index} of 0.25 showed that (28)18.4\% of the isolates was resistant to three antibiotics, MAR\textsubscript{index} of 0.375, 0.5, 0.625, 0.75 and 1.0 showed that (27)17.7\%, (11)7.2\%, (13)8.6\%, (9)5.9\% and (12)7.9\% of the isolates were resistant to at least three to six antibiotics, respectively. However, being resistant to three antibiotics, (65)42.8\% of the isolates were considered multidrug resistant strains.
Table 1: Susceptibility profile and multidrug antibiotic resistance index of *Staphylococcus aureus* isolated from asymptomatic nasal cavity

| Number of Isolates | MAR<sub>index</sub> | Antibiotics | No. of classes of antibiotics | Number of Isolate(s) | MAR<sub>index</sub> | Antibiotics | No. of classes of antibiotics |
|--------------------|---------------------|-------------|-------------------------------|---------------------|---------------------|-------------|-------------------------------|
| 28                 | 0.000               | None        | None                          | 1                   | 0.375               | Cfx-Ery-Clx | 3                             |
| 4                  | 0.125               | Cef         | 1                             | 1                   | 0.375               | Cof-Tet-Chl | 3                             |
| 1                  | 0.125               | Cfx         | 1                             | 3                   | 0.375               | Cef-Cfx-Clx | 2                             |
| 2                  | 0.125               | Gen         | 1                             | 7                   | 0.375               | Cfx-Aug-Cot | 3                             |
| 1                  | 0.125               | Ery         | 1                             | 8                   | 0.375               | Cef-Clx-Aug | 3                             |
| 8                  | 0.125               | Clx         | 1                             | 1                   | 0.5                 | Ery-Clx-Aug-Chl | 4                             |
| 2                  | 0.125               | Ery         | 1                             | 1                   | 0.5                 | Cef-Cft-Clx-Aug | 3                             |
| 2                  | 0.125               | Cot         | 1                             | 1                   | 0.5                 | Cef-Cfx-Ery-Clx | 3                             |
| 2                  | 0.125               | Tet         | 1                             | 1                   | 0.5                 | Cef-Ctx-Cfx-Clx | 2                             |
| 4                  | 0.125               | Chl         | 1                             | 1                   | 0.5                 | Cef-Gen-Chl-Off | 4                             |
| 1                  | 0.25                | Cef-Clx     | 1                             | 1                   | 0.5                 | Cfx-Ery-Clx-Aug | 4                             |
| 2                  | 0.25                | Cef-Cfx     | 1                             | 1                   | 0.5                 | Ery-Clx-Str-Chl | 4                             |
| 1                  | 0.25                | Gen-Chl     | 2                             | 2                   | 0.5                 | Cef-Ctx-Chl-Aug | 3                             |
| 1                  | 0.25                | Clx-Chl     | 2                             | 2                   | 0.5                 | Cfx-Aug-Cot-Chl | 4                             |
| 4                  | 0.25                | Str-Chl     | 2                             | 1                   | 0.625               | Ery-Ctx-Str-Chl | 5                             |
| 2                  | 0.25                | Cef-Chl     | 2                             | 1                   | 0.625               | Gen-Chl-Aug-Chl | 5                             |
| 2                  | 0.25                | Ery-Ctx     | 2                             | 1                   | 0.625               | Ctx-Cot-Chl-Aug | 5                             |
| 2                  | 0.25                | Ery-Cof     | 2                             | 1                   | 0.625               | Cef-Cfx-Chl-Chl | 4                             |
| 3                  | 0.25                | Ctx-Chl     | 2                             | 2                   | 0.625               | Cef-Ctx-Chl-Chl | 4                             |
| 4                  | 0.25                | Ctx-Chl     | 2                             | 2                   | 0.625               | Ery-Ctx-Aug-Chl | 5                             |
| 6                  | 0.25                | Ctx-Cht     | 2                             | 2                   | 0.625               | Cef-Ctx-Chl-Aug | 4                             |
| 1                  | 0.375               | Ery-Ctx-Chl | 3                             | 3                   | 0.625               | Cef-Ctx-Chl-Aug | 3                             |
| 1                  | 0.375               | Cef-Ctx-Chl | 1                             | 1                   | 0.75                | Cef-Ctx-Chl-Chl | 4                             |
| 1                  | 0.375               | Ctx-Chl-Chl | 3                             | 1                   | 0.75                | Cef-Ctx-Chl-Chl | 4                             |
| 1                  | 0.375               | Aug-Chl-Chl | 3                             | 2                   | 0.75                | Ery-Chl-Aug-Chl | 6                             |
| 1                  | 0.375               | Cef-Chl-Ery | 2                             | 2                   | 0.75                | Cef-Chl-Ery-Chl | 6                             |
| 1                  | 0.375               | Ery-Ctx-Chl | 3                             | 3                   | 0.75                | Cef-Chl-Ery-Chl | 4                             |
| 1                  | 0.375               | Gen-Chl-Chl | 3                             | 1                   | 1                   | Cef-Chl-Gem-Chl | 6                             |

Key: Cef = Cefazidime, Cfx = Cefuroxime, Gen = Gentamicin, CB = Ceftriazone, Ery = Erythromycin, Clx = Cloxacillin, Of = Ofloxacin, Aug = Augmentin, Cot = Cotrimoxazole, Str = Streptomycin, Tet = Tetracycline, Chl = Chloramphenicol
On subjecting the coagulase positive *S. aureus* isolates to 2 µg/ml and 4 µg/ml vancomycin, (27)17.9% of the isolates were resistant to vancomycin at 2 µg/ml concentration while (43)28.5% of the isolates were resistant to this antibiotic at 4 µg/ml. Although (5)3.0% of the isolates were resistant at 2 µg/ml and sensitive at 4 µg/ml, (27)17.8% were resistant at 2 µg/ml, (43)28.3% were resistant at 4 µg/ml and (27)17.9% of the isolates were simultaneously resistant to both concentrations as shown in Figure 2. From case definition of CLSI [24] indicating vancomycin MIC of ≤ 2 µg/ml as vancomycin-susceptible *S. aureus* (VSSA), vancomycin MIC = 4-8 µg/ml as vancomycin-intermediate *S. aureus* (VISA) and vancomycin MIC ≥ 16 µg/ml as vancomycin-resistant *S. aureus* (VISA), the isolates, in this study, may be grouped as being vancomycin sensitive *S. aureus* (VRSA) and vancomycin intermediate *S. aureus* (VISA).

Figure 2: Percentage of *Staphylococcus aureus* resistant to different concentrations of vancomycin

**Discussion**

Epidemiologically, the increase in the drug-resistant virulent bacterial strains has become a serious problem in the treatment and control of staphylococcal infections. Vancomycin-resistant *Staphylococcus aureus* (VRSA), gradually becoming important pathogens and endemic, are on the increase worldwide. Although there have been increase in the levels of resistance among bacteria isolated from patients with nosocomial infections, with methicillin-resistant *S. aureus* increasingly becoming nosocomial pathogens, vancomycin treatment failure or a worse clinical outcome and increasing vancomycin minimum inhibitory concentrations (MICs) have been reported. These have resulted in prolonged hospital stay, continued antibiotic therapy and rising health care expenses, morbidity and mortality.

In this study, the isolates were more resistant to the β-lactam antibiotics having a broad spectrum of activity against Gram-positive and Gram-negative bacteria but showed varied degree of resistance to the other classes of antibiotics. The resistance may be due to their exposure to cephalosporins, vancomycin and many commonly used antimicrobial agents including semisynthetic penicillins, macrolides, tetracyclines and aminoglycosides, production of low-affinity penicillin-binding proteins, expression of drug-destroying enzymes such as β-lactamases, altered drug targets as well as decreased bacterial permeability and increased drug efflux. The levels of multi-drug resistance of these isolates from asymptomatic individuals are alarming and confirm the assertion that healthy members of the community represent the largest reservoir of bacteria resistant to antimicrobial agents. The resistant colonies recorded within inhibition zones suggested heterogeneous resistant nature of some of the isolates. Contrary to this study, Close et al. indicated that the prevalence of the heterogeneously resistant strains may be up to 22% in some clinical isolates.

Although *S. aureus* colonize the skin and anterior nares, such colonization which can easily be transmitted by formites or direct contact with other healthy individuals may be transient or persistent or spread faster during upper respiratory tract viral infections. Therefore, to prevent the development of untreatable staphylococcal infections due to spread of vancomycin resistance, it becomes inevitable to determine their susceptibility to glycopeptides after the resistance of *enterococci* and *staphylococci* to such antimicrobials have been previ-
ously described.43 Hence, while the vancomycin minimum inhibitory concentration required to inhibit most strains of *S. aureus* is typically between 0.5 and 2 µg/ml,44 (27)17.86% were resistant at 2 µg/ml, (43)28.29% were resistant at 4 µg/ml and (27)17.86% of the isolates were resistant to both concentrations. Contrary to expectation, more strains were susceptible at lower concentrations of 2 µg/ml than was obtained at 4 µg/ml µg/ml. While Arthur et al.45 and Reddy et al.46 indicated that vancomycin resistance is mediated by vanA and vanB gene clusters altering the target for vancomycin from D-alanine-D-alanine to D-alanine-D-lactate which eventually results in blocking the release of terminal D-alanine and interchain bond formation, the mechanism of resistance in *S. aureus* has been linked to cell wall thickening limiting the access of vancomycin to the cytoplasmic membrane where the functional targets of vancomycin are located.47,48

**Conclusion**
The emergence and spread of multi-drug and vancomycin resistance is a threat to the already challenged therapy of staphylococcal infections. Its transmission to both immunocompetent and immunocompromised individuals could constitute a significant public health challenge. In this study, the presence of VISA in asymptomatic individuals could constitute a significant public health challenge. In this study, the presence of VISA in asymptomatic individuals is considered a critical concern to be addressed. Therefore, while minimizing antibiotic pressure and use to control the emergence of resistant strains in the hospital and in the community, clinicians and community must not only nurture culture resulting in infection prevention but also abide by practices that prevent transmission of potential pathogenic organisms. The study, therefore, indicates that asymptomatic individuals are carrying multi-drug and vancomycin intermediate resistant *S. aureus* to a great extent and a more sustainable therapy must be in place to prevent its dissemination or the outbreak of its infection to create significant public health challenges.

**Conflicts of interest**
Authors hereby declare that they have no conflict of interest.

**References**
1. dos Santos AL, Santos DO, de Freitas CC, Ferreira BL, Afonso IF, Rodrigues CR, et al. Staphylococcus aureus: visitando uma cepa de importância hospitalar. *J Bras Patol Med Lab* 2007; 43(6):413-23.
2. Von Eiff C, Becker K, Machka, K, Stammer H, Peters G. Nasal carriage as a source of *Staphylococcus aureus* bacteremia. Study Group. *New Engl J Med*. 2001; 344:11-16.
3. Vonberg PR, Stamm-Balderjahn S, Hansen S, Zuschneid I, Ruden H, Behnke M, Gastmeier P. How Often Do Asymptomatic Healthcare Workers Cause Methicillin-Resistant *Staphylococcus aureus* Outbreaks? A systematic evaluation. *Infect Contr Hosp Epidemiol* 2006, 27(10):1123-27.
4. Mimica MJ, Mendes CMF. Diagnóstico laboratorial da resistência à oxacilina em *Staphylococcus aureus*. *J Bras Patol Med Lab* 2007; 43:399-406.
5. Weese JS, Archambault M, Willey BM, Hearn P, Kreiswirth BN, Said-Salim B, McGeer A, Likhoshvay Y, Prescott JF, Low DE. Methicillin-resistant *Staphylococcus aureus* in horses and horse personnel, 2000-2002. *Emerg Infect Dis* 2005; 11(3):430-5.
6. Lee DS, Kang MS, Hwang HJ, Eom SH, Yang JY, Lee MS, et al. Synergistic effect between dieckol from Ecklonia stolonifera and β-lactams against methicillin-lin-resistant *Staphylococcus aureus*. *Biotechnol Bioprocess Eng*. 2008; 13:758-764 PubMed.
7. O’Brien FG, Lim TT, Chong FN, Coombs GW, Enright MC, Robinson DA, et al. Diversity among community isolates of Methicillin resistant *Staphylococcus aureus* in Australia. *J Clin Microbiol* 2004; 42(7):3185 - 3190.
8. Hiramatsu K, Aviaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *Lancet* 1997; 350:1670–1673.
9. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struclens MJ. Emergence of vancomycin-intermediate *Staphylococcus aureus* in a Belgian hospital: microbiological and clinical features. *J Antimicrob Chemother* 2002; 50:383–391.
10. Palazzo ICV, Araujo MLC, Darini ALC. First report of vancomycin-resistant *staphylococeci* isolated from healthy carriers in Brazil. *J Clin Microbiol* 2005; 43:179-85 PubMed.
11. Bataineh AB. Resistance of *Staphylococcus aureus* to vancomycin in Zarqa, Jordan *Pak J Med Sci* 2006; 22:144-8.
12. Al-Obeid S, Haddad Q, Cherkaoui A, Schrenzel J. Francois P. First detection of an invasive *Staphylococcus aureus* strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia. *J Clin Microbiol* 2010; 6:2199-204 PubMed.
13. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in *staphylococeci*. *Clin Microbiol Rev* 2002; 15:430 – 438.
14. Kollef MH. Limitations of vancomycin in the
management of resistant staphylococcal infections. Clin Infect Dis 2007; 45 (Suppl 3):S191-5.
15. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42(6):2398-2402.
16. Hsu DI, Hidayat IK, Quist R, Hindler J, Kalsson A, Wong-Beringer A. A comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32(5):378-385.
17. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46(2):193–200.
18. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother 2011; 66(7):1594–1599.
19. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54(6):755–771.
20. Forbes BA, Sahm DF, Weissfeld AS. Bailey and Scott's diagnostic microbiology. 12th ed. Mosby; 2007; p. 98-257.
21. Holt JG, Krieg NR, Sneath PHA, Williams ST. Staphylococcus spp. In: Bergey’s manual of determinative bacteriology, 9th ed. Baltimore, MD: Williams & Wilkins; 1994; p. 544-51.
22. Cheesbrough M. Medical Laboratory Manual for Tropical Countries, ELBS ed; Tropical health technology publications and Butterworth–Heinemann Ltd: Cambridge, UK, 2002; 2:2-392.
23. Cheesbrough M. District Laboratory Practice in Tropical Countries. Part 2: Cambridge University press, Cambridge, 2009; 62-69.
24. Clinical Laboratory Standards Institute (CLSI) 2016. Performance standards for Antimicrobial Susceptibility Testing (M100S), 26th edition. Clinical Laboratory Standards Institute, Wayne, PA.
25. Bauer AW, Kirby WM, Sherris JC, Truck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45:493-496.
26. Krumperman PH. Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of fecal contamination of foods. Appl Environ Microbiol 1983; 46(1):165-170.
27. Adeleke EO, Omofuvbe BO. Antibiotic resistance of aerobic mesophilic bacteria isolated from poultry faeces. Res J Microbiol. 2011; 6:356-365.
28. Gilbert M, MacDonald J, Louie M, Gregson D, Zhang K, Elsayed S, Laupland K, Nielsen D, Wheeler V, Lye T, Conly J. Prevalence of USA300 colonization or infection and associated variables during an outbreak of community-associated methicillin-resistant Staphylococcus aureus in a marginalized urban population. Can J Infect Dis Med Microbiol 2007; 18(6):357-62.
29. Ofrner-Agostini M, Johnson BL, Simor AE, Embil J, Matlow A, Mulvey M, Ormiston D, Conly J. Canadian Nosocomial Infection Surveillance Program Vancomycin-resistant enterococci in Canada: results from the Canadian Nosocomial infection Surveillance Program, 1999-2005. Infect Contr Hosp Epidemiol 2008; 29(3):271-4.
30. Kuiper EJ, Coignard B, Brazier J, Suetsens C, Drudy D, et al. Update of Clostridium difficile – associated disease due to PCR robust 027 in Europe. Eur. Surveill. 2007; 12:E1-2. Available: https://www.eurosurveillance.org/content/10.2807/esm.12.06.00714-en (accessed March 26, 2018).
31. Kesah C, Ben Redjeb SB, Oudghemi TO, Boye CS, Dosso M, Ndinya AJO, Koulla-Shiro S, Benbachir M, Rahal K, Borg M. Prevalence of methicillin resistant Staphylococcus aureus in eight African countries and Malta. Clin Microbiol Infect 2003; 9(2):153-156.
32. Rivera, A.M.; Boucher, H.W. Current concepts in antimicrobial therapy against selected Gram-positive organisms: Methicillin-resistant Staphylococcus aureus, penicillin-resistant Pneumococci, and vancomycin-resistant Enterococci. Mayo Clin Proc 2011; 86:1230-42 PubMed. 
33. Perry JD, Davies A, Butterworth LA, Hopley AL, Nicholson A, Gould FK. Development and evaluation of a chromogenic agar medium for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2004; 42:4519-23.
34. Petri WJ. Penicillins, Cephalosporins and Other β-Lactam Antibiotics. In: Brunton LL, Parker KL, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006; 728-750.
35. Pallares R, Pujol M, Pena C, Ariza J, Martic R, Gudini F. Cephalosporins as a risk factor for nosocomial Enterococcus faecalis bacteremia. Arch Intern Med 1993; 153:1581-6 PubMed.
36. Betriu C, Redondo M, Boloix A, Gomez M, Culebras E, Picazo JJ. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 2001; 48(6):911-913.
37. Fontana R, Cerini R, Lunguni P, Grossato A, Canepari P. Identification of a streptococcal penicillin-binding protein that treats very slowly with penicillin. J Bacteriol 1983; 155:1343-50.
38. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A Clinical Update. Clin Microbiol Rev 2005; 18:657–686 PubMed.
39. Piddock LJ. Clinically relevant chromosomally encoded multi-drug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19:382–402 PubMed.
40. Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-Sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacother 2002; 22(8):983-989.
41. Morell E, Balkin D. Methicillin-resistant Staphylococcus aureus: A pervasive pathogen highlights the need for new antimicrobial development. Yale J Biol Med 2010; 83:223-233 PubMed.
42. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2002; 13(4):686 PubMed.
43. Trueba F, Garrabe E, Hadef R, Fabre R, Cavall JD, Tsvetkova K, et al. High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol 2006; 44(5):1922 PubMed.
44. Centers for Disease Control and Prevention. Laboratory detection of vancomycin intermediate/resistant Staphylococcus aureus (VISA/VRSA) (Internet). Atlanta (GA): CDC. C2010 — (cited 2012 Aug. 29). Available from: http://www.cdc.gov/HAI/settings/lab/visa_vrsa_lab_detection.html.
45. Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol 1996; 4:401-407 PubMed.
46. Reddy CM, Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin-resistant Staphylococcus aureus isolates in Rayalaseema region Andhra Pradesh, South India. World J Sci Tech 2012; 2:6-8 PubMed.
47. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EN, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41(1):5-14.
48. Cui L, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y, Hiramatsu K. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:428–438.